The Future of Healthcare Investing
Healthcare is one of the most compelling long-term investment themes. As the global population ages, medical technology continues to advance, and patients seek better diagnosis, treatment, and care, the sector is poised for sustained growth. However, not every healthcare stock will perform well, but there are several companies that could become long-term winners.
Three ASX 200 healthcare shares that stand out for future investment are discussed below.
ResMed Inc (ASX: RMD)
ResMed is one of the top-rated healthcare companies on the ASX 200. The company is a global leader in sleep health, offering products that help treat conditions like sleep apnoea and other respiratory issues. What makes ResMed particularly attractive is its business model, which combines devices with recurring revenue from masks, accessories, and software.
This recurring revenue stream is crucial. Patients don’t just purchase a device once and move on; they often need replacement parts, ongoing support, and tools to manage their therapy effectively. This creates a stable and predictable income source.
Additionally, the market for sleep apnoea treatments remains underpenetrated. Many people with the condition remain undiagnosed, and awareness of the issue is still growing. While there has been much discussion about GLP-1 weight loss drugs and their impact on sleep apnoea, I see them more as an awareness driver rather than a threat. Increased health engagement can lead to more diagnoses and, ultimately, more demand for ResMed’s solutions.
Telix Pharmaceuticals Ltd (ASX: TLX)
Telix is a higher-risk healthcare growth stock, but it offers significant potential. The company focuses on radiopharmaceuticals used for cancer imaging and targeted treatment. This niche area of healthcare has the potential to revolutionize how certain cancers are detected and managed.
What sets Telix apart is that it isn’t just a clinical-stage dream. It already has a commercial base while continuing to invest in a pipeline that could drive future growth. This combination is appealing, although it comes with inherent risks. Clinical trials can face setbacks, regulatory timelines may shift, and investor patience can be tested when expectations are high.
Telix is not in the same risk category as a mature healthcare leader like ResMed, but for investors comfortable with volatility, it provides exposure to one of the most exciting areas of modern cancer care. If management can continue to grow the commercial business and advance its pipeline, the company could look very different in a decade.
Cochlear Ltd (ASX: COH)
Cochlear has faced challenges recently, but it still holds value for long-term investors. As a global leader in implantable hearing solutions, the company provides life-changing products for people with severe to profound hearing loss. The long-term demand for these solutions is clear, especially as populations age and awareness of hearing loss as a serious health issue grows.
Despite its strong fundamentals, Cochlear’s near-term outlook has been affected, and confidence in the company has waned. However, I believe the long-term need for its products hasn’t disappeared. The question for investors is whether the current challenges are temporary or structural. While I lean towards the former, recovery may take time.
Foolish Takeaway
Healthcare investing often requires patience. A company can have a strong long-term market and still face periods of negative sentiment. That’s why I focus on businesses with real clinical needs behind them, not just trendy stories.
These three ASX 200 shares come with different levels of risk, but each has a compelling reason to exist that should matter for years to come. Whether you’re looking for stability, growth, or innovation, there’s something here for every type of investor.
